REFERENCES
1. Tams TR. A diagnostic approach to vomiting in dogs and cats. Vet Med 1992;87(8):785-792.
2. Encarnacion HJ, Parra J, Mears E, et al. Vomiting. Compend Contin Educ Pract Vet 2009;31(3):122-131.
3. Plumb DC. Maropitant citrate. Plumb's veterinary drug handbook. 6th ed. Ames, Iowa: Blackwell Publishing, 2008;558-560.
4. de la Puente-Redondo VA, Siedek EM, Benchaoui HA, et al. The anti-emetic efficacy of maropitant (Cerenia) in the treatment
of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe. J Small Anim Pract 2007;48(2):93-98.
5. Benchaoui HA, Siedek EM, de la Puente-Redondo VA, et al. Efficacy of maropitant for preventing vomiting associated with
motion sickness in dogs. Vet Rec 2007;161(13):444-447.
6. Conder GA, Sedlacek HS, Boucher JF, et al. Efficacy and safety of maropitant, a selective neurokini n 1 receptor antagonist,
in two randomized clinical trials for prevention of vomiting due to motion sickness in dogs. J Vet Pharmacol Ther 2008;31(6):528-532.
7. The Merck veterinary manual. 9th ed. Whitehouse Station, N.J.: Merck & Co, 1998;1683.
8. de la Puente-Redondo VA, Tilt N, Rowan TG, et al. Efficacy of maropitant for treatment and prevention of emesis caused
by intravenous infusion of cisplatin in dogs. Am J Vet Res 2007;68(1):48-56.
9. Vail DM, Rodabaugh HS, Conder GA, et al. Efficacy of injectable maropitant (CERENIA) in a randomized clinical trial for
prevention and treatment of cisplatin-induced emesis in dogs presented as veterinary patients. Vet Comp Oncol 2007;5(1):38-46.
10. Kitchell BE. Advances in hemangiosarcoma treatment, in Proceedings. 33rd World Small Anim Vet Assoc Congress, 2008:505-507.
11. Pfizer Animal Health. Cerenia (maropitant citrate). Available at: http://pfizerah.com/Product_Overview.aspx?drug=CR&country=US&lang=EN&species=CN/. Accessed Aug. 17, 2009.
12. U.S. or Canadian product information: Cerenia, Pfizer Animal Health, U.S. and Canada.
13. Stella VJ, He Q. Cyclodextrins. Toxicol Pathol 2008;36(1):30-42.
14. Material Safety Data Sheet. Pfizer, May 2007.
15. Hickman MA, Cox SR, Mahabir S, et al. Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant
(Cerenia) for the prevention of emesis and motion sickness in cats. J Vet Pharmacol Ther 2008;31(3):220-229.
16. Freedom of information summary. Original New Animal Drug Application NADA 141-2621. CERENIA (maropitant citrate). Pfizer
Inc. January 2007.
17. Gogny M. Principe actif: le maropitant. Nouv Prat Vét Canine Féline 2008;8(39):69-70.
|
Featuring Information from:
